Our Programs


Drug Product Candidates under Development

Muscle cramps and spasms are involuntary, often painful, contractions that can last several minutes and, in many instances, result in prolonged soreness. Muscle cramps and spasms are thought to result from hyperexcitable alpha-motor neurons.  Spasticity is characterized by the combination of weakness and velocity-dependent resistance to stretch, in the same muscle.

At Flex Pharma, we are developing innovative and proprietary treatments to specifically treat cramping and spasticity associated with neurological disorders. 

Our lead drug product candidate, FLX-787, is currently being studied in an exploratory Phase 2 clinical trial in Australia in patients with multiple sclerosis, or MS, and in two Phase 2 clinical trials in the United States, including a study in ALS and Charcot-Marie Tooth (CMT) disease.